Patient info Open main menu

Nexavar 200 mg film-coated tablets – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
200 mg
Contains active substance:
ATC code:
Similar medicines:

Patient leaflet - Nexavar 200 mg film-coated tablets

1. What Nexavar is and what it is used for

Nexavar is used to treat liver cancer (hepatocellular carcinoma).

Nexavar is also used to treat kidney cancer (advanced renal cell carcinoma) at an advanced stage when standard therapy has not helped to stop your disease or is considered unsuitable. Nexavar is used to treat thyroid cancer (differentiated thyroid carcinoma). Nexavar is a so-called multikinase inhibitor. It works by slowing down the rate of growth of cancer cells and cutting off the blood supply that keeps cancer cells growing.

2. What do you need to know before you take Nexavar

Do not take Nexavar

  • If you are allergic to sorafenib or any of the other ingredients of this medicine (listed in

    section 6).

Warnings and precautions

Talk to your doctor or pharmacist before taking Nexavar.

Take special care with Nexavar

  • If you experience skin problems. Nexavar can cause rashes and skin reactions,

    especially on the hands and feet. These can usually be treated by your doctor. If not, your doctor may interrupt treatment or stop it altogether.

  • If you have high blood pressure. Nexavar can raise blood pressure, and your doctor will

    usually monitor your blood pressure and may give you a medicine to treat your high blood pressure.

  • If you have or have had an aneurysm (enlargement and weakening of a blood vessel

    wall) or a tear in a blood vessel wall.

  • If you have diabetes. Blood sugar levels in diabetic patients should be checked regularly

    in order to assess if anti-diabetic medicine’s dosage needs to be adjusted to minimize the risk of low blood sugar.

  • If you get any bleeding problems, or are taking warfarin or phenprocoumon.

    Treatment with Nexavar may lead to a higher risk of bleeding. If you are taking warfarin or phenprocoumon, medicines which thin the blood to prevent blood clots, there may be a greater risk of bleeding.

  • If you get chest pain or heart problems. Your doctor may decide to interrupt treatment

    or stop it altogether.

  • If you have a heart disorder, such as an abnormal electrical signal called “prolongation

    of the QT interval”.

  • If you are going to have surgery, or if you had an operation recently. Nexavar might

    affect the way your wounds heal. You will usually be taken off Nexavar if you are having an operation. Your doctor will decide when to start with Nexavar again. ■ If you are taking irinotecan or are given docetaxel, which are also medicines for

    cancer. Nexavar may increase the effects and, in particular, the side effects of these medicines.

  • If you are taking Neomycin or other antibiotics. The effect of Nexavar may be

    decreased.

  • If you have severe liver impairment. You may experience more severe side effects

    when taking this medicine.

  • If you have poor kidney function. Your doctor will monitor your fluid and electrolyte

    balance.

  • Fertility. Nexavar may reduce fertility in both men and women. If you are concerned, talk

    to a doctor.

    • Holes in the gut wall (gastrointestinal perforation) may occur during treatment (see

      section 4: Possible Side Effects). In this case your doctor will interrupt the treatment. ■ If you have thyroid cancer. Your doctor will monitor blood calcium and thyroid hormone

      levels.

    • If you experienced the following, contact your doctor immediately as this can be a

      life-threatening condition: nausea, shortness of breath, irregular heartbeat, muscular cramps, seizure, clouding of urine and tiredness. These may be caused by a group of metabolic complications that can occur during treatment of cancer that are caused by the break-down products of dying cancer cells (Tumour lysis syndrome (TLS)) and can lead to changes in kidney function and acute renal failure (see also section 4: Possible Side Effects).

Tell your doctor if any of these affect you. You may need treatment for them, or your doctor may decide to change your dose of Nexavar, or stop treatment altogether (see also section 4: Possible side effects).

Children and adolescents

Children and adolescents have not yet been tested with Nexavar.

Other medicines and Nexavar

Some medicines may affect Nexavar, or be affected by it. Tell your doctor or pharmacist if you are taking, have recently taken or might take anything in this list or any other medicines, including medicines obtained without a prescription:

  • Rifampicin, Neomycin or other medicines used to treat infections (antibiotics) ■ St John’s wort, a herbal treatment for depression
  • Phenytoin, carbamazepine or phenobarbital, treatments for epilepsy and other conditions ■ Dexamethasone, a corticosteroid used for various conditions
  • Warfarin or phenprocoumon, anticoagulants used to prevent blood clots ■ Doxorubicin, capecitabine, docetaxel, paclitaxel and irinotecan, which are cancer

    treatments

  • Digoxin, a treatment for mild to moderate heart failure

Pregnancy and breast-feeding

Avoid becoming pregnant while being treated with Nexavar. If you could become pregnant use adequate contraception during treatment. If you become pregnant while being treated with Nexavar, immediately tell your doctor who will decide if the treatment should be continued.

You must not breast-feed your baby during Nexavar treatment, as this medicine may interfere with the growth and development of your baby.

Driving and using machines

There is no evidence that Nexavar will affect the ability to drive or to operate machines.

Nexavar contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially “sodium free”.

3. How to take Nexavar

The recommended dose of Nexavar in adults is 2 x 200 mg tablets, twice daily.

This is equivalent to a daily dose of 800 mg or four tablets a day.

Swallow Nexavar tablets with a glass of water, either without food or with a low-fat or moderate fat meal. Do not take this medicine with high fat meals, as this may make Nexavar less effective. If you intend to have a high fat meal, take the tablets at least 1 hour before or 2 hours after the meal.

Always take this medicine exactly as your doctor has told you to. Check with your doctor or pharmacist if you are not sure.

It is important to take this medicine at about the same times each day, so that there is a steady amount in the bloodstream.

You will usually carry on taking this medicine as long as you are getting clinical benefits, and not suffering unacceptable side effects.

If you take more Nexavar than you should

Tell your doctor straight away if you (or anyone else) have taken more than your prescribed dose. Taking too much Nexavar makes side effects more likely or more severe, especially diarrhoea and skin reactions. Your doctor may tell you to stop taking this medicine.

If you forget to take Nexavar

If you have missed a dose, take it as soon as you remember. If it is nearly time for the next dose, forget about the missed one and carry on as normal. Do not take a double dose to make up for forgotten individual doses.

4. Possible side effects

Like all medicines, this medicine can cause side effects although not everybody gets them. This medicine may also affect the results of some blood tests.

Very common:

may affect more than 1 in 10 people

  • diarrhoea
  • feeling sick (nausea)
  • feeling weak or tired (fatigue)
  • pain (including mouth pain, abdominal pain, headache, bone pain, tumour pain) ■ hair loss (alopecia)
  • flushed or painful palms or soles (hand foot skin reaction)
  • itching or rash

    • throwing up (vomiting)
    • bleeding (including bleeding in the brain, gut wall and respiratory tract; haemorrhage) ■ high blood pressure, or increases in blood pressure (hypertension) ■ infections
    • loss of appetite (anorexia)
    • constipation
    • joint pain (arthralgia)
    • fever
    • weight loss
    • dry skin

Common:

may affect up to 1 in 10 people

  • flu-like illness
  • indigestion (dyspepsia)
  • difficulty swallowing (dysphagia)
  • inflamed or dry mouth, tongue pain (stomatitis and mucosal inflammation) ■ low calcium levels in the blood (hypocalcaemia)
  • low potassium levels in the blood (hypokalaemia)
  • low blood sugar level (hypoglycaemia)
  • muscle pain (myalgia)
  • disturbed sensations in fingers and toes, including tingling or numbness (peripheral

    sensory neuropathy)

  • depression
  • erection problems (impotence)
  • altered voice (dysphonia)
  • acne
  • inflamed, dry or scaly skin that sheds (dermatitis, skin desquamation) ■ heart failure
  • heart attack (myocardial infarction) or chest pain
  • tinnitus (ringing sound in the ear)
  • kidney failure
  • abnormally high levels of protein in the urine (proteinuria)
  • general weakness or loss of strength (asthenia)
  • decrease in the number of white blood cells (leucopenia and neutropenia) ■ decrease in the number of red blood cells (anaemia)
  • low number of platelets in the blood (thrombocytopenia)
  • inflammation of hair follicles (folliculitis)
  • underactive thyroid gland (hypothyroidism)
  • low sodium levels in the blood (hyponatraemia)
  • distortion of the sense of taste (dysgeusia)
  • red in the face and often other areas of the skin (flushing)
  • runny nose (rhinorrhoea)
  • heartburn (gastro oesophageal reflux disease)
  • skin cancer (keratoacanthomas/squamous cell cancer of the skin) ■ a thickening of the outer layer of the skin (hyperkeratosis)
  • a sudden, involuntary contraction of a muscle (muscle spasms) Uncommon:

may affect up to 1 in 100 people

  • inflamed stomach lining (gastritis)
  • pain in the tummy (abdomen) caused by pancreatitis, inflammation of the gall bladder and/

    or bile ducts

  • yellow skin or eyes (jaundice) caused by high levels of bile pigments (hyperbilirubinaemia) ■ allergic like reactions (including skin reactions and hives)
  • dehydration
  • enlarged breasts (gynaecomastia)
  • breathing difficulty (lung disease)
  • eczema
  • overactive thyroid gland (hyperthyroidism)
  • multiple skin eruptions (erythema multiforme)
  • abnormally high blood pressure
  • holes in the gut wall (gastrointestinal perforation)
  • reversible swelling in the rear part of the brain that can be associated with headache,

    altered consciousness, fits and visual symptoms including visual loss (reversible posterior leukoencephalopathy)

  • a sudden, severe allergic reaction (anaphylactic reaction)

Rare:

may affect up to 1 in 1,000 people

  • allergic reaction with swelling of the skin (e. g. face, tongue) that may cause difficulty in

    breathing or swallowing (angioedema)

  • abnormal heart rhythm (QT prolongation)
  • inflammation of the liver, which may lead to nausea, vomiting, abdominal pain, and

    jaundice (drug induced hepatitis)

  • a sunburn-like rash that may occur on skin that has previously been exposed to

    radiotherapy and can be severe (radiation recall dermatitis)

    • serious reactions of the skin and/or mucous membranes which may include painful blisters and fever, including extensive detachment of the skin (Stevens-Johnson syndrome and toxic epidermal necrolysis)
    • abnormal muscle breakdown which can lead to kidney problems (rhabdomyolysis) ■ damage of the kidney causing them to leak large amounts of protein (nephrotic syndrome) ■ inflammation of the vessels in the skin which may result in rash (leucocytoclastic vasculitis) Not known:

frequency cannot be estimated from the available data

  • impaired brain function that can be associated with e.g. drowsiness, behavioural changes, or confusion (encephalopathy)
  • an enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall

    (aneurysms and artery dissections)

  • nausea, shortness of breath, irregular heartbeat, muscular cramps, seizure, clouding of urine and tiredness (Tumour lysis syndrome (TLS)) (see section 2).

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Nexavar

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on each blister after EXP. The expiry date refers to the last day of that month.

Do not store this medicine above 25°C.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Nexavar contains

  • The active substance is sorafenib. Each film-coated tablet contains 200 mg sorafenib (as tosylate).
  • The other ingredients are:

    Tablet core: croscarmellose sodium, microcrystalline cellulose, hypromellose, sodium laurilsulfate, magnesium stearate.

    Tablet coating: hypromellose, macrogol, titanium dioxide (E 171), ferric oxide red (E 172).

What Nexavar looks like and contents of the pack

Nexavar 200 mg faceted film-coated tablets are red and round with the Bayer cross on one side and “200” on the other side. They come in calendar packs of 112 tablets: four transparent blister packs of 28 tablets each.

Marketing Authorisation Holder

Bayer plc

400 South Oak Way

Reading

RG2 6AD

Manufacturer

Bayer AG

Kaiser-Wilhelm-Allee

51368 Leverkusen

Germany

For any information about this medicine, please contact the Marketing Authorisation Holder. Bayer plc

Tel: +44 (0)118 206 3000

This package leaflet was last revised in 07/2024.

B

305x626-16865_15923

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLGB 00010/0701

Last revision stated in the text: July 2024 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Nexavar 200 mg film-coated tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Sorafenib
Strength 200 mg
Pharmaceutical form Oral tablet
How is it taken Oral
Pack sizes 112 tablet
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Drug group (ATC)
  1. L Antineoplastic and immunomodulating agents
    1. L01 Antineoplastic agents
      1. L01E Protein kinase inhibitors, antineoplastic and immunomodulating agents
        1. L01EX Other protein kinase inhibitors
          1. L01EX02 sorafenib
Marketing authorisation PLGB 00010/0701
Codes GTIN 4057598009362 · BNF 08010500

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.